ClinicalTrials.gg
RecruitingNCT06846671CaDAnCe-302Updated Nov 12, 2026

A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

A Phase 3 interventional study of Tacabrutideg and Bendamustine in CLL, Chronic Lymphocytic Leukemia and SLL, sponsored by BeOne Medicines. Recruiting at 134 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by BeOne Medicines · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.
Updated Nov 12, 2026Eligibility revised5 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Leukemia, Lymphocytic, Chronic, B-Cell by BeOne Medicines — 7 open to participants now, 12 under way, 7 of them phase 3. Leukemia, Lymphocytic, Chronic, B-Cell · BeOne Medicines.

Planned enrollment
9th of 18
250 · median 202
Started
2025
with 4 others
Phase 3
8 of 18
4 open now
Primary completion
2028-05
later than 6 of 11 live
Registered
14th of 18
by date

Among the 18 studies in Leukemia, Lymphocytic, Chronic, B-Cell by BeOne Medicines, this one is the 9th largest by planned enrollment, is one of 5 that started in 2025, is one of 8 in phase 3, reaches primary completion later than 6 of the 11 other live ones, and was the 14th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

7 of the 18 studies in Leukemia, Lymphocytic, Chronic, B-Cell by BeOne Medicines are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Leukemia, Lymphocytic, Chronic, B-Cell by BeOne Medicines, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the efficacy and safety of tacabrutideg compared with investigator's choice (idelalisib plus rituximab [for CLL only] or bendamustine plus rituximab or venetoclax plus rituximab retreatment) in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously exposed to both BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i).

Read the detailed description

CLL (chronic lymphocytic leukemia) and SLL (small lymphocytic lymphoma) are slow-growing blood cancers that affect the same type of white blood cell (called B lymphocytes). They are considered different forms of the same disease. CLL mainly occurs in the blood and bone marrow, while SLL mainly affects the lymph nodes.

Tacabrutideg is a type of medicine called a BTK degrader. BTK (Bruton's tyrosine kinase) is a protein that helps cancer cells survive. Tacabrutideg is designed to attach to the BTK protein and tag it for removal, so that the body's own cellular "clean-up" system breaks it down and clears it away. When more BTK is removed from the body, it interferes with the signals needed for the cancer cells to multiply and survive and may also help overcome resistance caused by certain changes in BTK.

The purpose of this study is to test if tacabrutideg is safe and if it works in adults with CLL or SLL. The main goal of the study is to find the amount of time participants live without their disease getting worse after starting the study treatment.

This study has two treatment groups. Participants will be randomly assigned by chance, to one of the treatment groups. Participants and the study doctors will know what treatment is received during the study.

The study will enroll approximately 250 adults at multiple centers worldwide with CLL or SLL. The overall time to participate in this study is 36 months. Participants will make regular visits to the clinic for treatment, health checks, blood tests, and tumor and imaging tests.

Our company, previously known as BeiGene, is now officially BeOne Medicines. Because some of our older studies were sponsored under the name BeiGene, you may see both names used for this study on this website.

03

Conditions studied

  • CLL
  • Chronic Lymphocytic Leukemia
  • SLL

Keywords

  • CLL
  • SLL
  • Bruton tyrosine kinase (BTK)
  • BTK-targeted protein degrader
04

Who can participate

The criteria were revised on the registry on Nov 12, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Confirmed diagnosis of CLL or SLL, requiring treatment, based on 2018 international workshop on chronic lymphocytic leukemia (iwCLL) criteria.
  2. Previously received treatment for CLL/SLL with both a BTKi and a BCL2i.
  3. Participants with SLL must have by computer tomography (CT)/magnetic resonance imaging (MRI).
  4. (ECOG) performance status 0, 1, or 2.
  5. Adequate liver function.
  6. Adequate blood clotting function.

Exclusion criteria

Exclusion Criteria:

  1. Known prolymphocytic leukemia (defined per iwCLL 2018 as prolymphocytes comprising >55% of peripheral blood lymphocytes), or currently suspected or history of Richter's transformation within the last 5 years.
  2. Prior stem cell transplant or chimeric antigen receptor-T cell therapy in the last 6 months.
  3. Known central nervous system involvement.
  4. Prior exposure to any BTK protein degraders.
  5. Active fungal, bacterial and/or viral infection requiring parenteral systemic therapy.
  6. cardiovascular disease.
  7. Prior invasive fungal infection, except if patient agrees to receive secondary antifungal prophylaxis during the entire treatment period.
  8. Known to azole antifungal agents, including reactions.
  9. Receiving systemic therapy for a nonmalignant condition within 28 days before the first dose of study treatment.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
250 participants (estimated)

Study arms

  • Experimental
    Arm A: Tacabrutideg monotherapy

    Participants will receive tacabrutideg once daily until any of the treatment discontinuation criteria are met

    Drug: Tacabrutideg

  • Active comparator
    Arm B: Investigator's Choice

    Participants will receive investigator's choice of idelalisib plus rituximab for CLL only or bendamustine plus rituximab, or venetoclax plus rituximab retreatment.

    Drug: Bendamustine · Drug: Idelalisib · Drug: Rituximab · Drug: Venetoclax

Interventions

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS) by Independent Review Committee (IRC)

    PFS is defined as time from the date of randomization to the date of first disease progression or death, whichever occurs first, as determined by IRC using modified 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria for participants with chronic lymphocytic leukemia (CLL) and Lugano classification for participants with small lymphocytic lymphoma (SLL).

    Time frame: Approximately 36 Months

Secondary outcomes

  1. Overall Survival (OS)

    OS is defined as time from the date of randomization to the date of death due to any cause.

    Time frame: Approximately 36 Months

  2. Progression-Free Survival (PFS) in Participants with Prior Exposure to Noncovalent Bruton Tyrosine Kinase Inhibitor(s) (ncBTKi) by IRC

    PFS is defined as time from the date of randomization to the date of first disease progression or death, whichever occurs first, as determined by IRC using modified 2018 iwCLL criteria for participants with chronic lymphocytic leukemia (CLL) and Lugano classification for participants with small lymphocytic lymphoma (SLL) for participants with prior exposure to ncBTKi.

    Time frame: Approximately 36 Months

  3. PFS by the Investigator Assessment

    PFS is defined as time from the date of randomization to the date of first disease progression or death, whichever occurs first, as determined by the investigator using modified 2018 iwCLL criteria for participants with CLL and Lugano classification for participants with SLL

    Time frame: Approximately 36 Months

  4. Overall Response Rate (ORR) by IRC and Investigator Assessment

    ORR is defined as the percentage of participants with best overall response of complete response (CR), complete response with incomplete bone marrow recovery (CRi), nodular partial remission (nPR), or partial response (PR) as assessed by the IRC or by the investigator.

    Time frame: Approximately 36 Months

  5. Rate of Partial Response with Lymphocytosis (PR-L) or Higher Determined by IRC and by Investigator Assessment

    Rate of PR-L or higher is defined as the percentage of participants with a best overall response of CR, CRi, nPR, PR, or PR-L as assessed by the IRC or by the Investigator

    Time frame: Approximately 36 Months

  6. Duration of Response (DOR) by IRC and Investigator Assessment

    DOR is defined as the time from initial response to disease progression or death, whichever occurs first, as assessed by the IRC or by the investigator.

    Time frame: Approximately 36 Months

  7. Time to Next Anti-CLL/SLL Treatment (TTNT)

    TTNT is defined as the time from the date of randomization to the date of next anti-CLL/SLL treatment.

    Time frame: Approximately 36 Months

  8. Number of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs), and Laboratory Abnormalities

    Safety will be assessed by monitoring and recording of all treatment emergent adverse events (AEs) graded by National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0.

    Time frame: Approximately 36 Months

  9. Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Cancer Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status/QoL (GHS) Physical Functioning and Role Functioning Scales

    The EORTC QLQ-C30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales(fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1=Not at all (best) to 4=Very Much (worst) and 2 questions answered on a 7-point scale where 1=Very poor (worst) to 7=Excellent (best). Higher scores in GHS and functional scales indicate better quality of life.

    Time frame: Approximately 24 Months

  10. Change from baseline in EORTC Quality of Life Questionnaire - Chronic Lymphocytic Leukemia Module 17 Items (QLQ-CLL17) Symptom Burden and Physical Condition Scales

    The symptom burden and physical condition will be measured by QLQ-CLL17. EORTC QLQ-CLL17 comprises 17 items grouped into 3 multi-item scales: 1) symptom burden, 2) physical condition/fatigue, and 3) worries/fears about health and functioning. Each question is rated using a 4-point response scale ("not at all," "a little," "quite a bit," and "very much") and the recall period for all items is the past 7 days. The scores of each subscale are calculated based on the EORTC's protocol and then transformed to a 0 to 100 scale. Higher scores represent higher levels of symptom burden, physical condition/fatigue, or worries/fears about health and functioning.

    Time frame: Approximately 24 Months

07

Study locations

134 of 134 sites recruiting

Showing the first 100 of 134 sites across 14 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — BeOne shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved. BeOne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations. Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeOne review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See plan description

Access criteria: See plan description

Data sharing details ↗ · beonemedicines.com

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for May 2028, 37 months after the start.

Of 57 industry-sponsored phase 3 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 73. This study's planned 37 months is below that.

Counting every sponsor, half of 83 studies reached it within 59 months; a quarter within 43 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2025
First posted
Feb 26, 2025
StartActual
Apr 10, 2025
Primary completionEst.
May 15, 2028
CompletionEst.
Feb 14, 2030
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
5 sites added, 1 site removed
Show 5 added (4 United States, 1 Brazil)
  • Intermountain Health Lutheran Hospital Cancer Center of Colorado · Golden, United States
  • University of Minnesota · Minneapolis, United States
  • Suny Upstate Medical University · Syracuse, United States
  • Baylor Scott and White Health Medical Center Temple · Temple, United States
  • Vida Hematologia · Novo Hamburgo, Brazil
Show 1 removed
  • Baylor Scott and White Health · Temple, United States
across 2 updates, Sep 28, 2026 – Nov 12, 2026
Eligibility
1 inclusion criterion edited; 2 exclusion criteria edited, 3 added
What changed in the criteria
Inclusion criteria
  • EditedEastern Cooperative Oncology Group (ECOG) scoreperformance status 0, 1, or 2.
Exclusion criteria
  • ChangedBefore Known prolymphocytic leukemia or history of, or currently suspected, Richter's transformationNow Known prolymphocytic leukemia (defined per iwCLL 2018 as prolymphocytes comprising >55% of peripheral blood lymphocytes), or currently suspected or history of Richter's transformation within the last 5 years.
  • EditedPrior autologous stem cell transplant or chimeric antigen receptor-T cell therapy in the last 36 months.
  • AddedPrior invasive fungal infection, except if patient agrees to receive secondary antifungal prophylaxis during the entire treatment period.
  • AddedKnown contraindications to azole antifungal agents, including hypersensitivity reactions.
  • AddedReceiving systemic immunosuppressive therapy for a nonmalignant condition within 28 days before the first dose of study treatment.
Nov 12, 2026
Secondary outcomes
2 edited, 2 description edited
What changed in the outcomes
  • EditedNumber of Participants With Treatment-emergent Adverse Events (TEAEs) and, Treatment Emergent-emergent Serious Adverse Events (TESAEs), and Laboratory AbnormalitiesTime frame: Approximately 36 Months
  • EditedChange from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Cancer Questionnaire -Core 30 (EORTC QLQ-C30) Global Health Status/QoL (GHS) and Physical Functioning and Role Functioning ScalesTime frame: Approximately 24 Months
  • DescriptionOverall Response Rate (ORR) by IRC and Investigator Assessment: how it is measured was reworded
  • DescriptionProgression-Free Survival (PFS) in Participants with Prior Exposure to Noncovalent Bruton Tyrosine Kinase Inhibitor(s) (ncBTKi) by IRC: how it is measured was reworded
Nov 12, 2026
Show all 2 updates
  1. Nov 12, 2026
    3 sites added, 1 site removed
    Show 3 added (2 United States, 1 Brazil)
    • Suny Upstate Medical University · Syracuse, United States
    • Baylor Scott and White Health Medical Center Temple · Temple, United States
    • Vida Hematologia · Novo Hamburgo, Brazil
    Show 1 removed
    • Baylor Scott and White Health · Temple, United States
    Eligibility 1 inclusion criterion edited; 2 exclusion criteria edited, 3 added
    What changed in the criteria
    Inclusion criteria
    • EditedEastern Cooperative Oncology Group (ECOG) scoreperformance status 0, 1, or 2.
    Exclusion criteria
    • ChangedBefore Known prolymphocytic leukemia or history of, or currently suspected, Richter's transformationNow Known prolymphocytic leukemia (defined per iwCLL 2018 as prolymphocytes comprising >55% of peripheral blood lymphocytes), or currently suspected or history of Richter's transformation within the last 5 years.
    • EditedPrior autologous stem cell transplant or chimeric antigen receptor-T cell therapy in the last 36 months.
    • AddedPrior invasive fungal infection, except if patient agrees to receive secondary antifungal prophylaxis during the entire treatment period.
    • AddedKnown contraindications to azole antifungal agents, including hypersensitivity reactions.
    • AddedReceiving systemic immunosuppressive therapy for a nonmalignant condition within 28 days before the first dose of study treatment.
    Secondary outcomes 2 edited, 2 description edited
    What changed in the outcomes
    • EditedNumber of Participants With Treatment-emergent Adverse Events (TEAEs) and, Treatment Emergent-emergent Serious Adverse Events (TESAEs), and Laboratory AbnormalitiesTime frame: Approximately 36 Months
    • EditedChange from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Cancer Questionnaire -Core 30 (EORTC QLQ-C30) Global Health Status/QoL (GHS) and Physical Functioning and Role Functioning ScalesTime frame: Approximately 24 Months
    • DescriptionOverall Response Rate (ORR) by IRC and Investigator Assessment: how it is measured was reworded
    • DescriptionProgression-Free Survival (PFS) in Participants with Prior Exposure to Noncovalent Bruton Tyrosine Kinase Inhibitor(s) (ncBTKi) by IRC: how it is measured was reworded
    + 3 other changes: verification date, description and conditions
  2. Sep 28, 2026
    2 sites added
    Show 2 added (2 United States)
    • Intermountain Health Lutheran Hospital Cancer Center of Colorado · Golden, United States
    • University of Minnesota · Minneapolis, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06846671
Lead sponsor
BeOne Medicines
Responsible party
Sponsor
First posted
Feb 26, 2025
Start date
Apr 10, 2025
Primary completion
May 15, 2028 (estimated)
Completion
Feb 14, 2030 (estimated)
Last update
Nov 12, 2026

Study contacts

Study Director
Contact
clinicaltrials@beonemed.com
1.877.828.5568
Study Director
study director · BeOne Medicines

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tacabrutideg

Start the discussion